BioSpecifics Technologies Corp (BSTC) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
35 WILBUR ST LYNBROOK, NY 11563 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2020 MRQ | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 89,239 | 80,884 | 59,308 | 49,018 | 33,485 | 20,711 | |||
| Cash and cash equivalent | 4,999 | 13,176 | 7,334 | 4,763 | 5,138 | 9,811 | |||
| Short-term investments | 84,240 | 67,707 | 51,974 | 44,255 | 28,348 | 10,900 | |||
| Receivables | 19,066 | 16,519 | 4,655 | 4,306 | 3,465 | 3,640 | |||
| Capitalized contract cost | 185 | ✕ | ✕ | ✕ | ✕ | ||||
| Deferred costs | 1,794 | 1,452 | 1,018 | 570 | |||||
| Other undisclosed current assets | 966 | 647 | 624 | 624 | 401 | 228 | |||
| Total current assets: | 109,271 | 98,234 | 66,381 | 55,400 | 38,369 | 25,149 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 239 | ✕ | ✕ | ✕ | ✕ | ✕ | |||
| Long-term investments and receivables | 16,569 | 1,100 | 5,746 | 3,771 | 3,597 | 1,250 | |||
| Long-term investments | 16,569 | 1,100 | 5,746 | 3,771 | 3,597 | 1,250 | |||
| Intangible assets, net (including goodwill) | 573 | 444 | 398 | 258 | 275 | 295 | |||
| Intangible assets, net (excluding goodwill) | 573 | 444 | 398 | 258 | 275 | 295 | |||
| Deferred costs | 732 | 1,976 | 2,851 | 3,271 | |||||
| Other undisclosed noncurrent assets | 314 | 1,740 | 3,290 | 606 | 1,062 | ||||
| Total noncurrent assets: | 17,382 | 1,858 | 8,616 | 9,296 | 7,329 | 5,878 | |||
| TOTAL ASSETS: | 126,653 | 100,092 | 74,996 | 64,696 | 45,698 | 31,027 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 998 | 1,799 | 934 | 739 | 611 | 544 | |||
| Taxes payable | 355 | 69 | |||||||
| Employee-related liabilities | 209 | 173 | 215 | 183 | 165 | 169 | |||
| Accrued liabilities | 364 | 1,503 | 151 | 51 | 74 | 65 | |||
| Other undisclosed accounts payable and accrued liabilities | 70 | 122 | 499 | 505 | 372 | 309 | |||
| Debt | 69 | ||||||||
| Deferred revenue and credits | ✕ | ✕ | ✕ | 1,058 | 1,180 | 149 | 49 | ||
| Other undisclosed current liabilities | 355 | 705 | 147 | 78 | 78 | 78 | |||
| Total current liabilities: | 1,422 | 2,504 | 2,139 | 1,997 | 839 | 671 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation: | 167 | ||||||||
| Liabilities, other than long-term debt | 573 | 5,341 | 6,418 | 49 | 99 | ||||
| Deferred revenue and credits | ✕ | ✕ | ✕ | 5,341 | 6,418 | 49 | 99 | ||
| Deferred income tax liabilities | 573 | ✕ | ✕ | ✕ | ✕ | ✕ | |||
| Operating lease, liability | 167 | ✕ | ✕ | ✕ | ✕ | ✕ | |||
| Total noncurrent liabilities: | 740 | 5,341 | 6,418 | 49 | 99 | ||||
| Total liabilities: | 2,162 | 2,504 | 7,480 | 8,414 | 888 | 770 | |||
| Equity | |||||||||
| Equity, attributable to parent | 124,491 | 97,589 | 67,517 | 56,282 | 44,810 | 30,257 | |||
| Common stock | 8 | 8 | 8 | 8 | 7 | 7 | |||
| Treasury stock, value | (11,519) | (10,898) | (7,898) | (7,282) | (6,233) | (4,431) | |||
| Additional paid in capital | 39,356 | 36,302 | 33,468 | 32,945 | 31,797 | 25,059 | |||
| Retained earnings | 96,647 | 72,177 | 41,939 | 30,611 | 19,239 | 9,621 | |||
| Total equity: | 124,491 | 97,589 | 67,517 | 56,282 | 44,810 | 30,257 | |||
| TOTAL LIABILITIES AND EQUITY: | 126,653 | 100,092 | 74,996 | 64,696 | 45,698 | 31,027 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2020 TTM | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 38,188 | 32,961 | 27,444 | 26,251 | 22,750 | 14,077 | ||
| Revenue, net | ✕ | ✕ | ✕ | 27,444 | 26,251 | 22,750 | 14,077 | |
| Gross profit: | 38,188 | 32,961 | 27,444 | 26,251 | 22,750 | 14,077 | ||
| Operating expenses | (9,876) | (9,563) | (9,766) | (9,225) | (8,307) | (7,877) | ||
| Other undisclosed operating income | 799 | |||||||
| Operating income: | 28,312 | 23,399 | 17,678 | 17,026 | 14,443 | 6,999 | ||
| Nonoperating income | 1,987 | 1,399 | 688 | 349 | 108 | 33 | ||
| Investment income, nonoperating | 1,987 | 1,295 | 637 | 296 | 93 | 32 | ||
| Other nonoperating income (expense) | (0) | 104 | 51 | 53 | 15 | 1 | ||
| Income from continuing operations before income taxes: | 30,299 | 24,797 | 18,366 | 17,375 | 14,551 | 7,033 | ||
| Income tax expense | (5,829) | (4,744) | (7,038) | (6,003) | (4,933) | (2,387) | ||
| Income from continuing operations: | 24,470 | 20,053 | 11,328 | 11,372 | 9,618 | 4,646 | ||
| Income before gain (loss) on sale of properties: | ✕ | 24,470 | 20,053 | 11,328 | 11,372 | 9,618 | 4,646 | |
| Net income available to common stockholders, diluted: | 24,470 | 20,053 | 11,328 | 11,372 | 9,618 | 4,646 | ||
Comprehensive Income ($ in thousands)
| 9/30/2020 TTM | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|---|---|---|---|
| Net income: | 24,470 | 20,053 | 11,328 | 11,372 | 9,618 | 4,646 | ||
| Comprehensive income, net of tax, attributable to parent: | 24,470 | 20,053 | 11,328 | 11,372 | 9,618 | 4,646 | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.